Institutional investors hold a majority ownership of CASC through the 62.42% of the outstanding shares that they control. This interest is also higher than at almost any other company in the Biotechnology industry. Last, during the quarter ended September 2017, these large investors purchased a net $654.3 thousand shares.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
BLACKROCK FUND ADVISORS Bought 718.8 Thousand shares of Cascadian Therapeutics In...